 Asokumar Buvanendran
Concepts (491)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pain, Postoperative | 42 | 2023 | 321 | 8.540 |
Why?
| | Analgesics, Opioid | 33 | 2023 | 224 | 7.050 |
Why?
| | Pain Management | 23 | 2021 | 145 | 5.250 |
Why?
| | Analgesics | 25 | 2023 | 113 | 4.640 |
Why?
| | Chronic Pain | 27 | 2023 | 111 | 4.290 |
Why?
| | Low Back Pain | 25 | 2021 | 140 | 4.030 |
Why?
| | Pain Measurement | 42 | 2020 | 479 | 3.570 |
Why?
| | Analgesia | 11 | 2021 | 40 | 3.360 |
Why?
| | Morphine | 20 | 2021 | 79 | 3.340 |
Why?
| | Complex Regional Pain Syndromes | 8 | 2020 | 24 | 2.860 |
Why?
| | Arthroplasty, Replacement, Knee | 14 | 2021 | 705 | 2.630 |
Why?
| | Nerve Block | 13 | 2020 | 63 | 2.570 |
Why?
| | Opioid-Related Disorders | 5 | 2021 | 63 | 2.380 |
Why?
| | Anesthetics, Local | 11 | 2016 | 88 | 2.200 |
Why?
| | Disease Models, Animal | 12 | 2022 | 844 | 2.180 |
Why?
| | gamma-Aminobutyric Acid | 11 | 2012 | 51 | 2.000 |
Why?
| | Anesthesia, Conduction | 12 | 2021 | 33 | 1.990 |
Why?
| | Spinal Cord Stimulation | 6 | 2022 | 13 | 1.860 |
Why?
| | Dexamethasone | 5 | 2016 | 54 | 1.820 |
Why?
| | Ketamine | 6 | 2019 | 32 | 1.800 |
Why?
| | Cyclooxygenase Inhibitors | 8 | 2016 | 38 | 1.760 |
Why?
| | Bupivacaine | 5 | 2016 | 56 | 1.760 |
Why?
| | Humans | 118 | 2023 | 32988 | 1.710 |
Why?
| | Acute Pain | 6 | 2023 | 21 | 1.600 |
Why?
| | Pain | 13 | 2021 | 407 | 1.560 |
Why?
| | Arthroplasty, Replacement, Hip | 9 | 2017 | 889 | 1.390 |
Why?
| | Surgical Wound Infection | 4 | 2018 | 106 | 1.380 |
Why?
| | Ketorolac | 4 | 2016 | 17 | 1.280 |
Why?
| | Male | 75 | 2022 | 17726 | 1.270 |
Why?
| | Anti-Inflammatory Agents | 4 | 2016 | 111 | 1.260 |
Why?
| | Female | 67 | 2022 | 18423 | 1.260 |
Why?
| | Motor Activity | 7 | 2017 | 391 | 1.190 |
Why?
| | Middle Aged | 50 | 2021 | 11219 | 1.130 |
Why?
| | Animals | 30 | 2022 | 5371 | 1.100 |
Why?
| | Pain Threshold | 7 | 2021 | 22 | 1.100 |
Why?
| | Cyclooxygenase 2 Inhibitors | 9 | 2010 | 30 | 1.090 |
Why?
| | Platelet Aggregation Inhibitors | 5 | 2018 | 68 | 1.080 |
Why?
| | Injections, Spinal | 5 | 2019 | 48 | 1.070 |
Why?
| | Zygapophyseal Joint | 5 | 2020 | 48 | 1.060 |
Why?
| | Inflammation Mediators | 3 | 2017 | 97 | 1.050 |
Why?
| | Electric Stimulation Therapy | 7 | 2022 | 44 | 1.030 |
Why?
| | Rats, Sprague-Dawley | 20 | 2018 | 484 | 0.980 |
Why?
| | Spouses | 7 | 2019 | 28 | 0.970 |
Why?
| | Anesthesia, Epidural | 4 | 2015 | 29 | 0.960 |
Why?
| | Analgesia, Patient-Controlled | 5 | 2017 | 26 | 0.960 |
Why?
| | AMP-Activated Protein Kinases | 2 | 2022 | 17 | 0.950 |
Why?
| | Minimally Invasive Surgical Procedures | 3 | 2021 | 319 | 0.920 |
Why?
| | Adult | 39 | 2021 | 9848 | 0.910 |
Why?
| | Spine | 4 | 2021 | 125 | 0.890 |
Why?
| | Sciatic Nerve | 5 | 2016 | 33 | 0.870 |
Why?
| | Glucocorticoids | 4 | 2020 | 80 | 0.870 |
Why?
| | Anger | 3 | 2017 | 33 | 0.860 |
Why?
| | Clonidine | 6 | 2016 | 32 | 0.850 |
Why?
| | Lumbar Vertebrae | 5 | 2021 | 504 | 0.850 |
Why?
| | Arthralgia | 4 | 2020 | 125 | 0.850 |
Why?
| | Lactones | 3 | 2007 | 14 | 0.840 |
Why?
| | Cytokines | 4 | 2015 | 372 | 0.830 |
Why?
| | Neuralgia | 3 | 2019 | 16 | 0.810 |
Why?
| | Analgesia, Epidural | 6 | 2017 | 61 | 0.800 |
Why?
| | Anesthesia, Obstetrical | 2 | 2015 | 12 | 0.790 |
Why?
| | Electrodes, Implanted | 5 | 2018 | 51 | 0.790 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 7 | 2020 | 113 | 0.780 |
Why?
| | Double-Blind Method | 17 | 2023 | 546 | 0.770 |
Why?
| | Prospective Studies | 12 | 2021 | 2002 | 0.770 |
Why?
| | Abdominal Muscles | 1 | 2020 | 7 | 0.750 |
Why?
| | Antiemetics | 1 | 2020 | 7 | 0.750 |
Why?
| | Metformin | 1 | 2020 | 20 | 0.750 |
Why?
| | Sulfones | 4 | 2010 | 26 | 0.740 |
Why?
| | Time-to-Treatment | 1 | 2020 | 37 | 0.740 |
Why?
| | Aged | 28 | 2021 | 10542 | 0.740 |
Why?
| | Edema | 1 | 2020 | 39 | 0.740 |
Why?
| | Central Nervous System | 3 | 2010 | 66 | 0.730 |
Why?
| | Program Evaluation | 1 | 2020 | 150 | 0.730 |
Why?
| | Mice | 8 | 2022 | 1958 | 0.720 |
Why?
| | Hyperalgesia | 6 | 2022 | 51 | 0.720 |
Why?
| | Treatment Outcome | 19 | 2021 | 4036 | 0.710 |
Why?
| | Bariatric Surgery | 1 | 2020 | 45 | 0.710 |
Why?
| | Catastrophization | 5 | 2021 | 15 | 0.690 |
Why?
| | Osteoarthritis, Knee | 2 | 2021 | 384 | 0.680 |
Why?
| | Interpersonal Relations | 6 | 2019 | 114 | 0.680 |
Why?
| | Vancomycin | 1 | 2018 | 57 | 0.670 |
Why?
| | Anesthesia | 2 | 2010 | 35 | 0.670 |
Why?
| | Anti-Bacterial Agents | 2 | 2018 | 434 | 0.640 |
Why?
| | Mice, Inbred C57BL | 5 | 2022 | 563 | 0.640 |
Why?
| | Ultrasonography, Interventional | 3 | 2019 | 75 | 0.630 |
Why?
| | Laparotomy | 2 | 2016 | 24 | 0.620 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 4 | 2012 | 35 | 0.620 |
Why?
| | Administration, Intravenous | 2 | 2017 | 35 | 0.610 |
Why?
| | Spinal Fusion | 4 | 2021 | 526 | 0.610 |
Why?
| | Societies, Medical | 7 | 2020 | 214 | 0.610 |
Why?
| | Cyclohexanecarboxylic Acids | 4 | 2012 | 16 | 0.610 |
Why?
| | Amines | 4 | 2012 | 17 | 0.610 |
Why?
| | Buprenorphine | 1 | 2016 | 7 | 0.590 |
Why?
| | Anticoagulants | 6 | 2018 | 153 | 0.580 |
Why?
| | Equipment Failure | 1 | 2016 | 56 | 0.570 |
Why?
| | Epidural Space | 3 | 2015 | 24 | 0.570 |
Why?
| | International Cooperation | 1 | 2015 | 36 | 0.560 |
Why?
| | Cervical Vertebrae | 3 | 2016 | 365 | 0.550 |
Why?
| | Joints | 1 | 2016 | 101 | 0.550 |
Why?
| | Health Surveys | 1 | 2015 | 102 | 0.540 |
Why?
| | Platelet Function Tests | 1 | 2015 | 5 | 0.540 |
Why?
| | Ticlopidine | 1 | 2015 | 14 | 0.530 |
Why?
| | Random Allocation | 4 | 2020 | 162 | 0.530 |
Why?
| | Magnetic Resonance Imaging, Interventional | 1 | 2014 | 8 | 0.530 |
Why?
| | Medication Errors | 1 | 2015 | 20 | 0.530 |
Why?
| | Rats | 16 | 2022 | 972 | 0.520 |
Why?
| | Acetaminophen | 4 | 2023 | 23 | 0.520 |
Why?
| | Steroids | 1 | 2014 | 31 | 0.520 |
Why?
| | Infusion Pumps | 1 | 2014 | 16 | 0.520 |
Why?
| | Dinoprostone | 4 | 2007 | 33 | 0.510 |
Why?
| | Pregnancy Complications | 1 | 2015 | 59 | 0.510 |
Why?
| | General Surgery | 1 | 2015 | 62 | 0.510 |
Why?
| | Time Factors | 11 | 2018 | 1873 | 0.510 |
Why?
| | Patient Satisfaction | 3 | 2017 | 325 | 0.500 |
Why?
| | Young Adult | 10 | 2018 | 2287 | 0.500 |
Why?
| | Infection Control | 1 | 2015 | 172 | 0.500 |
Why?
| | Consensus | 8 | 2022 | 121 | 0.500 |
Why?
| | Hematoma, Epidural, Spinal | 1 | 2014 | 4 | 0.500 |
Why?
| | Practice Guidelines as Topic | 5 | 2020 | 388 | 0.500 |
Why?
| | Spinal Cord | 4 | 2012 | 107 | 0.490 |
Why?
| | Models, Animal | 2 | 2016 | 147 | 0.470 |
Why?
| | Severity of Illness Index | 3 | 2015 | 1242 | 0.470 |
Why?
| | Aspirin | 1 | 2014 | 96 | 0.460 |
Why?
| | Naloxone | 6 | 2019 | 12 | 0.450 |
Why?
| | Length of Stay | 4 | 2021 | 382 | 0.440 |
Why?
| | Calcitonin Gene-Related Peptide | 1 | 2011 | 16 | 0.430 |
Why?
| | Substance P | 1 | 2011 | 19 | 0.430 |
Why?
| | Catheter Ablation | 3 | 2018 | 88 | 0.430 |
Why?
| | Norepinephrine | 1 | 2011 | 33 | 0.430 |
Why?
| | Chronic Disease | 7 | 2010 | 554 | 0.430 |
Why?
| | Phantom Limb | 2 | 2008 | 4 | 0.430 |
Why?
| | Glutamic Acid | 1 | 2011 | 36 | 0.430 |
Why?
| | Drug Administration Schedule | 6 | 2018 | 249 | 0.420 |
Why?
| | Hypoglycemic Agents | 3 | 2020 | 70 | 0.420 |
Why?
| | Combined Modality Therapy | 6 | 2018 | 449 | 0.420 |
Why?
| | Evidence-Based Medicine | 6 | 2018 | 235 | 0.410 |
Why?
| | Postoperative Complications | 3 | 2021 | 1117 | 0.410 |
Why?
| | Cohort Studies | 5 | 2021 | 2077 | 0.410 |
Why?
| | Blood Patch, Epidural | 2 | 2008 | 9 | 0.400 |
Why?
| | Positron-Emission Tomography | 2 | 2010 | 102 | 0.400 |
Why?
| | Dermatologic Surgical Procedures | 1 | 2010 | 13 | 0.400 |
Why?
| | Injections | 5 | 2020 | 59 | 0.400 |
Why?
| | Ambulatory Surgical Procedures | 1 | 2011 | 78 | 0.370 |
Why?
| | Neutrophils | 2 | 2016 | 139 | 0.370 |
Why?
| | Ganglia, Spinal | 2 | 2022 | 60 | 0.370 |
Why?
| | Denervation | 3 | 2020 | 23 | 0.370 |
Why?
| | United States | 12 | 2021 | 2632 | 0.370 |
Why?
| | Isoenzymes | 3 | 2004 | 59 | 0.370 |
Why?
| | Diabetes Mellitus, Experimental | 4 | 2015 | 35 | 0.360 |
Why?
| | Cross-Over Studies | 7 | 2018 | 86 | 0.360 |
Why?
| | Hostility | 3 | 2018 | 22 | 0.360 |
Why?
| | Wound Healing | 1 | 2010 | 178 | 0.360 |
Why?
| | Hip Joint | 3 | 2012 | 370 | 0.360 |
Why?
| | Drug Delivery Systems | 2 | 2019 | 42 | 0.360 |
Why?
| | Behavior, Animal | 4 | 2016 | 110 | 0.360 |
Why?
| | Brain Mapping | 1 | 2010 | 194 | 0.350 |
Why?
| | Brain | 2 | 2010 | 1752 | 0.350 |
Why?
| | Hematoma, Subdural, Intracranial | 1 | 2008 | 3 | 0.350 |
Why?
| | Opioid Peptides | 4 | 2020 | 6 | 0.350 |
Why?
| | Subdural Effusion | 1 | 2008 | 7 | 0.350 |
Why?
| | Chicago | 4 | 2015 | 957 | 0.340 |
Why?
| | Memantine | 1 | 2008 | 13 | 0.340 |
Why?
| | Pilot Projects | 3 | 2020 | 466 | 0.340 |
Why?
| | Physicians, Family | 1 | 2008 | 7 | 0.330 |
Why?
| | Administration, Oral | 3 | 2018 | 158 | 0.320 |
Why?
| | Specialization | 1 | 2008 | 22 | 0.320 |
Why?
| | Sleep | 3 | 2019 | 388 | 0.320 |
Why?
| | Decompression, Surgical | 2 | 2021 | 145 | 0.310 |
Why?
| | Neoplasms | 1 | 2010 | 280 | 0.310 |
Why?
| | Diclofenac | 1 | 2007 | 4 | 0.310 |
Why?
| | Ossification, Heterotopic | 1 | 2007 | 42 | 0.310 |
Why?
| | Gene Expression Regulation | 1 | 2009 | 350 | 0.310 |
Why?
| | Referral and Consultation | 1 | 2008 | 102 | 0.300 |
Why?
| | Cyclooxygenase 2 | 5 | 2008 | 32 | 0.300 |
Why?
| | Drug Combinations | 2 | 2016 | 89 | 0.300 |
Why?
| | Narcotic Antagonists | 5 | 2017 | 14 | 0.300 |
Why?
| | Preoperative Care | 1 | 2007 | 148 | 0.290 |
Why?
| | Interleukins | 1 | 2006 | 43 | 0.280 |
Why?
| | Adrenal Cortex Hormones | 2 | 2018 | 113 | 0.280 |
Why?
| | Risk Factors | 6 | 2018 | 2762 | 0.270 |
Why?
| | Orthopedics | 1 | 2007 | 133 | 0.270 |
Why?
| | Thoracotomy | 1 | 2004 | 37 | 0.260 |
Why?
| | Athletic Injuries | 1 | 2006 | 182 | 0.260 |
Why?
| | Adaptation, Psychological | 4 | 2018 | 185 | 0.250 |
Why?
| | Superior Vena Cava Syndrome | 1 | 2004 | 8 | 0.250 |
Why?
| | Retrospective Studies | 7 | 2021 | 3835 | 0.250 |
Why?
| | Perioperative Care | 3 | 2018 | 74 | 0.240 |
Why?
| | Postoperative Period | 5 | 2019 | 298 | 0.240 |
Why?
| | Fentanyl | 1 | 2003 | 21 | 0.240 |
Why?
| | Adrenergic alpha-Agonists | 3 | 2009 | 18 | 0.240 |
Why?
| | Drug Therapy, Combination | 3 | 2016 | 261 | 0.240 |
Why?
| | Acute Kidney Injury | 1 | 2004 | 67 | 0.230 |
Why?
| | Magnesium | 1 | 2003 | 48 | 0.230 |
Why?
| | Insulin | 2 | 2015 | 117 | 0.230 |
Why?
| | Catheterization | 2 | 2015 | 62 | 0.230 |
Why?
| | Injections, Intra-Articular | 4 | 2020 | 90 | 0.230 |
Why?
| | Exploratory Behavior | 2 | 2016 | 23 | 0.230 |
Why?
| | Affect | 3 | 2019 | 71 | 0.230 |
Why?
| | Pregnancy | 3 | 2015 | 466 | 0.230 |
Why?
| | Aged, 80 and over | 5 | 2020 | 5249 | 0.220 |
Why?
| | Self Report | 3 | 2019 | 245 | 0.220 |
Why?
| | Spinal Puncture | 3 | 2022 | 28 | 0.220 |
Why?
| | Lidocaine | 4 | 2012 | 41 | 0.210 |
Why?
| | Headache Disorders | 2 | 2014 | 4 | 0.210 |
Why?
| | Adrenergic alpha-2 Receptor Agonists | 2 | 2012 | 2 | 0.210 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2020 | 377 | 0.210 |
Why?
| | Knee Joint | 3 | 2018 | 812 | 0.210 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 4 | 2006 | 26 | 0.210 |
Why?
| | Ontario | 1 | 2021 | 18 | 0.200 |
Why?
| | Radiography | 3 | 2015 | 717 | 0.200 |
Why?
| | Adolescent | 4 | 2018 | 2687 | 0.200 |
Why?
| | Cesarean Section | 2 | 2015 | 34 | 0.200 |
Why?
| | Anticonvulsants | 2 | 2012 | 111 | 0.190 |
Why?
| | Telemedicine | 2 | 2020 | 117 | 0.190 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 2 | 2010 | 16 | 0.190 |
Why?
| | Tibial Fractures | 1 | 2020 | 13 | 0.190 |
Why?
| | Activities of Daily Living | 4 | 2018 | 515 | 0.190 |
Why?
| | Up-Regulation | 5 | 2008 | 225 | 0.190 |
Why?
| | Anesthesiology | 1 | 2020 | 30 | 0.190 |
Why?
| | Off-Label Use | 1 | 2019 | 6 | 0.180 |
Why?
| | Illness Behavior | 1 | 2019 | 3 | 0.180 |
Why?
| | Endocannabinoids | 1 | 2019 | 3 | 0.180 |
Why?
| | Uncertainty | 1 | 2019 | 9 | 0.180 |
Why?
| | Physician's Role | 1 | 2019 | 22 | 0.180 |
Why?
| | Oxycodone | 1 | 2019 | 6 | 0.180 |
Why?
| | Musculoskeletal Pain | 1 | 2019 | 20 | 0.180 |
Why?
| | Hospitals | 1 | 2020 | 159 | 0.180 |
Why?
| | Social Perception | 1 | 2019 | 24 | 0.170 |
Why?
| | Rodentia | 1 | 2018 | 8 | 0.170 |
Why?
| | Clinical Trials as Topic | 2 | 2014 | 368 | 0.170 |
Why?
| | Incidence | 2 | 2015 | 840 | 0.170 |
Why?
| | Physicians | 1 | 2021 | 136 | 0.170 |
Why?
| | Drug Prescriptions | 1 | 2019 | 40 | 0.170 |
Why?
| | Anesthesia, Spinal | 2 | 2015 | 19 | 0.170 |
Why?
| | Coronavirus Infections | 1 | 2020 | 96 | 0.170 |
Why?
| | Excitatory Amino Acid Antagonists | 2 | 2009 | 23 | 0.170 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 101 | 0.170 |
Why?
| | Betamethasone | 1 | 2018 | 3 | 0.170 |
Why?
| | Ischemia | 2 | 2017 | 35 | 0.170 |
Why?
| | Triamcinolone Acetonide | 1 | 2018 | 7 | 0.160 |
Why?
| | Sacroiliac Joint | 1 | 2018 | 9 | 0.160 |
Why?
| | Marriage | 1 | 2018 | 9 | 0.160 |
Why?
| | Affective Symptoms | 1 | 2018 | 12 | 0.160 |
Why?
| | Laparoscopy | 1 | 2020 | 193 | 0.160 |
Why?
| | Methylprednisolone | 1 | 2018 | 22 | 0.160 |
Why?
| | Peripheral Nervous System Diseases | 2 | 2009 | 36 | 0.160 |
Why?
| | Arousal | 2 | 2015 | 52 | 0.160 |
Why?
| | Triage | 2 | 2020 | 31 | 0.160 |
Why?
| | Amides | 2 | 2010 | 21 | 0.160 |
Why?
| | Classification | 1 | 2017 | 3 | 0.160 |
Why?
| | Medical History Taking | 1 | 2017 | 26 | 0.160 |
Why?
| | beta-Endorphin | 1 | 2017 | 1 | 0.150 |
Why?
| | Symptom Assessment | 1 | 2017 | 24 | 0.150 |
Why?
| | Patient Selection | 3 | 2014 | 261 | 0.150 |
Why?
| | Knee | 1 | 2017 | 47 | 0.150 |
Why?
| | Mood Disorders | 1 | 2017 | 37 | 0.150 |
Why?
| | Wound Closure Techniques | 1 | 2016 | 11 | 0.150 |
Why?
| | Injections, Epidural | 2 | 2015 | 17 | 0.150 |
Why?
| | Dose-Response Relationship, Drug | 6 | 2012 | 494 | 0.150 |
Why?
| | Anticipation, Psychological | 1 | 2016 | 8 | 0.150 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2019 | 233 | 0.150 |
Why?
| | Cyclooxygenase 1 | 2 | 2008 | 7 | 0.150 |
Why?
| | Neuralgia, Postherpetic | 1 | 2015 | 2 | 0.140 |
Why?
| | Reproducibility of Results | 3 | 2014 | 893 | 0.140 |
Why?
| | Herpes Zoster | 1 | 2015 | 4 | 0.140 |
Why?
| | Research Design | 1 | 2018 | 244 | 0.140 |
Why?
| | Pseudomonas Infections | 1 | 2016 | 64 | 0.140 |
Why?
| | Oxygen | 1 | 2016 | 105 | 0.140 |
Why?
| | Pseudomonas aeruginosa | 1 | 2016 | 89 | 0.140 |
Why?
| | Diagnostic Self Evaluation | 1 | 2015 | 17 | 0.140 |
Why?
| | Ibuprofen | 1 | 2015 | 12 | 0.130 |
Why?
| | Sex Distribution | 1 | 2015 | 92 | 0.130 |
Why?
| | Catheters | 1 | 2015 | 10 | 0.130 |
Why?
| | Age Distribution | 1 | 2015 | 109 | 0.130 |
Why?
| | Joint Capsule | 1 | 2015 | 45 | 0.130 |
Why?
| | Health Care Surveys | 1 | 2015 | 77 | 0.130 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2015 | 39 | 0.130 |
Why?
| | Autoantibodies | 1 | 2015 | 119 | 0.130 |
Why?
| | Infusions, Intravenous | 4 | 2018 | 87 | 0.130 |
Why?
| | Muscle Spasticity | 1 | 2014 | 16 | 0.130 |
Why?
| | Social Behavior | 1 | 2015 | 106 | 0.130 |
Why?
| | Orthopedic Procedures | 1 | 2018 | 320 | 0.130 |
Why?
| | Endpoint Determination | 1 | 2014 | 31 | 0.130 |
Why?
| | Algorithms | 1 | 2017 | 428 | 0.130 |
Why?
| | Pain Clinics | 1 | 2014 | 6 | 0.130 |
Why?
| | Blood Glucose | 1 | 2015 | 135 | 0.130 |
Why?
| | Migraine Disorders | 1 | 2014 | 26 | 0.130 |
Why?
| | Anesthesia, General | 1 | 2014 | 33 | 0.120 |
Why?
| | Recovery of Function | 2 | 2017 | 312 | 0.120 |
Why?
| | Patient Safety | 1 | 2014 | 55 | 0.120 |
Why?
| | Range of Motion, Articular | 2 | 2009 | 710 | 0.120 |
Why?
| | Cross-Sectional Studies | 5 | 2019 | 1058 | 0.120 |
Why?
| | Regression Analysis | 3 | 2019 | 326 | 0.120 |
Why?
| | Nervous System Diseases | 1 | 2015 | 159 | 0.110 |
Why?
| | Staphylococcal Infections | 1 | 2015 | 183 | 0.110 |
Why?
| | Skin | 2 | 2010 | 136 | 0.110 |
Why?
| | Quality of Life | 1 | 2018 | 747 | 0.110 |
Why?
| | Longitudinal Studies | 1 | 2017 | 1485 | 0.110 |
Why?
| | Membrane Proteins | 2 | 2004 | 220 | 0.110 |
Why?
| | Phenols | 1 | 2012 | 11 | 0.110 |
Why?
| | Capsaicin | 1 | 2012 | 12 | 0.110 |
Why?
| | Perioperative Period | 1 | 2011 | 13 | 0.110 |
Why?
| | Osteoarthritis, Spine | 1 | 2011 | 7 | 0.110 |
Why?
| | Hospitalization | 1 | 2015 | 367 | 0.110 |
Why?
| | Exercise | 3 | 2021 | 494 | 0.100 |
Why?
| | Interleukin-6 | 2 | 2015 | 123 | 0.100 |
Why?
| | International Normalized Ratio | 1 | 2011 | 33 | 0.100 |
Why?
| | Intracranial Hypotension | 2 | 2008 | 7 | 0.100 |
Why?
| | Back Pain | 1 | 2011 | 63 | 0.100 |
Why?
| | Biological Availability | 1 | 2010 | 26 | 0.100 |
Why?
| | Blood Loss, Surgical | 2 | 2018 | 69 | 0.100 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2010 | 42 | 0.100 |
Why?
| | Radioisotopes | 1 | 2010 | 16 | 0.100 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2011 | 46 | 0.100 |
Why?
| | Warfarin | 1 | 2011 | 61 | 0.100 |
Why?
| | Preoperative Period | 1 | 2010 | 71 | 0.100 |
Why?
| | Peripheral Nerves | 2 | 2014 | 20 | 0.100 |
Why?
| | Diabetic Neuropathies | 1 | 2010 | 15 | 0.100 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2010 | 40 | 0.100 |
Why?
| | Physical Stimulation | 2 | 2013 | 17 | 0.100 |
Why?
| | Epinephrine | 4 | 2012 | 32 | 0.100 |
Why?
| | Neostigmine | 2 | 2007 | 6 | 0.090 |
Why?
| | Intervertebral Disc Degeneration | 1 | 2011 | 127 | 0.090 |
Why?
| | Interleukin-18 Receptor alpha Subunit | 1 | 2009 | 2 | 0.090 |
Why?
| | Interleukin-18 Receptor beta Subunit | 1 | 2009 | 2 | 0.090 |
Why?
| | Chemokine CCL20 | 1 | 2009 | 2 | 0.090 |
Why?
| | Macrophage Migration-Inhibitory Factors | 1 | 2009 | 3 | 0.090 |
Why?
| | Pyridines | 1 | 2010 | 47 | 0.090 |
Why?
| | Muscle, Skeletal | 2 | 2015 | 391 | 0.090 |
Why?
| | Area Under Curve | 2 | 2010 | 77 | 0.090 |
Why?
| | Databases as Topic | 1 | 2009 | 22 | 0.090 |
Why?
| | Psychometrics | 1 | 2010 | 292 | 0.090 |
Why?
| | Posterior Horn Cells | 1 | 2008 | 5 | 0.080 |
Why?
| | Postoperative Nausea and Vomiting | 2 | 2006 | 18 | 0.080 |
Why?
| | Interprofessional Relations | 1 | 2008 | 43 | 0.080 |
Why?
| | Treatment Failure | 1 | 2008 | 186 | 0.080 |
Why?
| | Recurrence | 1 | 2008 | 400 | 0.080 |
Why?
| | Pain, Intractable | 1 | 2007 | 16 | 0.080 |
Why?
| | Terrorism | 1 | 2007 | 15 | 0.080 |
Why?
| | Quality of Health Care | 1 | 2009 | 151 | 0.080 |
Why?
| | Drug Interactions | 1 | 2007 | 70 | 0.080 |
Why?
| | Microglia | 1 | 2008 | 133 | 0.080 |
Why?
| | United States Food and Drug Administration | 2 | 2019 | 74 | 0.080 |
Why?
| | Neuronal Plasticity | 1 | 2007 | 50 | 0.080 |
Why?
| | Drug Synergism | 2 | 2004 | 67 | 0.080 |
Why?
| | Europe | 2 | 2017 | 85 | 0.070 |
Why?
| | Sulfonamides | 1 | 2006 | 60 | 0.070 |
Why?
| | Intraoperative Period | 1 | 2006 | 35 | 0.070 |
Why?
| | Cartilage, Articular | 1 | 2011 | 587 | 0.070 |
Why?
| | Depression | 3 | 2019 | 533 | 0.070 |
Why?
| | Interleukin-8 | 1 | 2006 | 41 | 0.070 |
Why?
| | Pyrazoles | 1 | 2006 | 53 | 0.070 |
Why?
| | Interleukin-1 | 1 | 2006 | 91 | 0.070 |
Why?
| | Electronic Health Records | 2 | 2018 | 84 | 0.070 |
Why?
| | Depressive Disorder | 1 | 2007 | 208 | 0.070 |
Why?
| | Arachnoiditis | 1 | 2005 | 5 | 0.070 |
Why?
| | Cauda Equina | 1 | 2005 | 6 | 0.070 |
Why?
| | Reoperation | 1 | 2010 | 970 | 0.070 |
Why?
| | Vascular Surgical Procedures | 1 | 2006 | 55 | 0.070 |
Why?
| | Arthroplasty, Replacement | 1 | 2007 | 149 | 0.070 |
Why?
| | Follow-Up Studies | 2 | 2008 | 2053 | 0.070 |
Why?
| | Peripheral Nerve Injuries | 2 | 2015 | 16 | 0.070 |
Why?
| | Tissue Fixation | 1 | 2004 | 11 | 0.070 |
Why?
| | Cold Temperature | 1 | 2004 | 37 | 0.070 |
Why?
| | Ribs | 1 | 2004 | 18 | 0.070 |
Why?
| | Transcranial Magnetic Stimulation | 2 | 2014 | 17 | 0.060 |
Why?
| | Sex Factors | 3 | 2014 | 548 | 0.060 |
Why?
| | Herb-Drug Interactions | 1 | 2004 | 1 | 0.060 |
Why?
| | Nonprescription Drugs | 1 | 2004 | 2 | 0.060 |
Why?
| | Plant Preparations | 1 | 2004 | 10 | 0.060 |
Why?
| | Mediastinal Neoplasms | 1 | 2004 | 14 | 0.060 |
Why?
| | Weight Gain | 1 | 2004 | 75 | 0.060 |
Why?
| | Dyssomnias | 1 | 2003 | 8 | 0.060 |
Why?
| | Hydrocodone | 1 | 2023 | 5 | 0.060 |
Why?
| | Neurosurgery | 2 | 2014 | 48 | 0.060 |
Why?
| | Social Support | 2 | 2015 | 226 | 0.060 |
Why?
| | Risk Assessment | 1 | 2006 | 814 | 0.060 |
Why?
| | Adenosine Monophosphate | 1 | 2022 | 6 | 0.060 |
Why?
| | Mammals | 1 | 2022 | 29 | 0.060 |
Why?
| | Proteomics | 1 | 2023 | 90 | 0.060 |
Why?
| | Intracranial Pressure | 1 | 2002 | 26 | 0.060 |
Why?
| | Ion Channels | 1 | 2004 | 237 | 0.050 |
Why?
| | Trigger Points | 1 | 2020 | 1 | 0.050 |
Why?
| | United States Department of Veterans Affairs | 1 | 2020 | 11 | 0.050 |
Why?
| | Appointments and Schedules | 1 | 2020 | 15 | 0.050 |
Why?
| | Military Medicine | 1 | 2020 | 15 | 0.050 |
Why?
| | Disinfection | 1 | 2020 | 13 | 0.050 |
Why?
| | Fellowships and Scholarships | 1 | 2021 | 44 | 0.050 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2020 | 24 | 0.050 |
Why?
| | Substance Withdrawal Syndrome | 1 | 2020 | 38 | 0.050 |
Why?
| | Public Health | 1 | 2020 | 69 | 0.050 |
Why?
| | Radio Waves | 1 | 2020 | 8 | 0.050 |
Why?
| | Infusion Pumps, Implantable | 1 | 2019 | 13 | 0.050 |
Why?
| | Health Services Accessibility | 1 | 2020 | 115 | 0.050 |
Why?
| | Breast Neoplasms | 1 | 2004 | 435 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 1 | 2004 | 899 | 0.040 |
Why?
| | Diagnosis, Differential | 2 | 2010 | 462 | 0.040 |
Why?
| | Mass Screening | 1 | 2020 | 203 | 0.040 |
Why?
| | Pandemics | 1 | 2020 | 253 | 0.040 |
Why?
| | Forecasting | 1 | 2019 | 136 | 0.040 |
Why?
| | Medical Records | 1 | 2018 | 36 | 0.040 |
Why?
| | Disability Evaluation | 2 | 2014 | 340 | 0.040 |
Why?
| | Postoperative Hemorrhage | 1 | 2018 | 29 | 0.040 |
Why?
| | Thigh | 1 | 2017 | 35 | 0.040 |
Why?
| | Anxiety | 1 | 2019 | 180 | 0.040 |
Why?
| | Public-Private Sector Partnerships | 1 | 2017 | 5 | 0.040 |
Why?
| | Venous Thromboembolism | 1 | 2018 | 58 | 0.040 |
Why?
| | Administration, Intravesical | 1 | 2017 | 4 | 0.040 |
Why?
| | Pain Perception | 1 | 2017 | 7 | 0.040 |
Why?
| | Hot Temperature | 1 | 2017 | 26 | 0.040 |
Why?
| | Rest | 1 | 2017 | 32 | 0.040 |
Why?
| | Herpesvirus 3, Human | 1 | 2015 | 5 | 0.040 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2015 | 29 | 0.030 |
Why?
| | Computers, Handheld | 1 | 2015 | 14 | 0.030 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2017 | 376 | 0.030 |
Why?
| | Streptozocin | 1 | 2015 | 7 | 0.030 |
Why?
| | Sex Characteristics | 1 | 2017 | 139 | 0.030 |
Why?
| | Anatomic Landmarks | 1 | 2015 | 8 | 0.030 |
Why?
| | North America | 1 | 2015 | 42 | 0.030 |
Why?
| | Interferon-gamma | 1 | 2015 | 119 | 0.030 |
Why?
| | Dissection | 1 | 2015 | 29 | 0.030 |
Why?
| | Interferon-alpha | 1 | 2015 | 69 | 0.030 |
Why?
| | Empathy | 1 | 2015 | 47 | 0.030 |
Why?
| | Flatulence | 1 | 2015 | 1 | 0.030 |
Why?
| | Internationality | 1 | 2015 | 26 | 0.030 |
Why?
| | Models, Psychological | 1 | 2015 | 89 | 0.030 |
Why?
| | Perception | 1 | 2015 | 91 | 0.030 |
Why?
| | Walking | 1 | 2017 | 277 | 0.030 |
Why?
| | Optogenetics | 1 | 2014 | 1 | 0.030 |
Why?
| | Facial Pain | 1 | 2014 | 7 | 0.030 |
Why?
| | Registries | 1 | 2016 | 226 | 0.030 |
Why?
| | Equipment Safety | 1 | 2014 | 14 | 0.030 |
Why?
| | Neuronavigation | 1 | 2014 | 9 | 0.030 |
Why?
| | Vagus Nerve Stimulation | 1 | 2014 | 8 | 0.030 |
Why?
| | Angina Pectoris | 1 | 2014 | 18 | 0.030 |
Why?
| | Wound Infection | 1 | 2014 | 13 | 0.030 |
Why?
| | Hematoma | 1 | 2014 | 25 | 0.030 |
Why?
| | Headache | 1 | 2014 | 56 | 0.030 |
Why?
| | Checklist | 1 | 2014 | 43 | 0.030 |
Why?
| | Stem Cell Transplantation | 1 | 2014 | 52 | 0.030 |
Why?
| | Risk Reduction Behavior | 1 | 2014 | 61 | 0.030 |
Why?
| | Spinal Cord Injuries | 1 | 2014 | 48 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 2014 | 159 | 0.030 |
Why?
| | Diskectomy | 1 | 2016 | 197 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 2013 | 156 | 0.030 |
Why?
| | Deep Brain Stimulation | 1 | 2014 | 94 | 0.030 |
Why?
| | Vasoconstrictor Agents | 1 | 2012 | 30 | 0.030 |
Why?
| | Patient Education as Topic | 1 | 2014 | 193 | 0.030 |
Why?
| | Implants, Experimental | 1 | 2012 | 29 | 0.030 |
Why?
| | Mental Disorders | 1 | 2014 | 206 | 0.030 |
Why?
| | Catheters, Indwelling | 1 | 2011 | 29 | 0.030 |
Why?
| | Adrenergic Agonists | 1 | 2010 | 5 | 0.020 |
Why?
| | Sensation | 1 | 2010 | 17 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2012 | 626 | 0.020 |
Why?
| | Prevalence | 1 | 2012 | 554 | 0.020 |
Why?
| | Absorption | 1 | 2010 | 3 | 0.020 |
Why?
| | Prostaglandins E | 1 | 2010 | 6 | 0.020 |
Why?
| | Tissue Distribution | 1 | 2010 | 52 | 0.020 |
Why?
| | Nerve Degeneration | 1 | 2010 | 57 | 0.020 |
Why?
| | Chromatography, Liquid | 1 | 2010 | 26 | 0.020 |
Why?
| | Tandem Mass Spectrometry | 1 | 2010 | 28 | 0.020 |
Why?
| | Information Management | 1 | 2009 | 1 | 0.020 |
Why?
| | Cardiovascular Diseases | 1 | 2014 | 446 | 0.020 |
Why?
| | Prognosis | 1 | 2012 | 1011 | 0.020 |
Why?
| | Program Development | 1 | 2009 | 75 | 0.020 |
Why?
| | Quality Indicators, Health Care | 1 | 2009 | 45 | 0.020 |
Why?
| | Data Collection | 1 | 2009 | 118 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2010 | 592 | 0.020 |
Why?
| | Databases, Factual | 1 | 2010 | 393 | 0.020 |
Why?
| | Internet | 1 | 2009 | 112 | 0.020 |
Why?
| | September 11 Terrorist Attacks | 1 | 2007 | 11 | 0.020 |
Why?
| | Causality | 1 | 2007 | 60 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2008 | 471 | 0.020 |
Why?
| | Isoflurane | 1 | 2006 | 10 | 0.020 |
Why?
| | Thoracic Surgical Procedures | 1 | 2006 | 12 | 0.020 |
Why?
| | Anxiety Disorders | 1 | 2007 | 179 | 0.020 |
Why?
| | Vocalization, Animal | 1 | 2005 | 6 | 0.020 |
Why?
| | Lower Extremity | 1 | 2006 | 43 | 0.020 |
Why?
| | Tissue Adhesions | 1 | 2005 | 10 | 0.020 |
Why?
| | Lumbosacral Region | 1 | 2005 | 73 | 0.020 |
Why?
| | Receptors, Adrenergic, alpha | 1 | 2004 | 3 | 0.020 |
Why?
| | Colforsin | 1 | 2004 | 13 | 0.020 |
Why?
| | Pyrimidines | 1 | 2004 | 26 | 0.020 |
Why?
| | Indans | 1 | 2004 | 9 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2004 | 244 | 0.020 |
Why?
| | Acetates | 1 | 2003 | 26 | 0.020 |
Why?
| | Cholinesterase Inhibitors | 1 | 2003 | 19 | 0.020 |
Why?
| | Foot | 1 | 2003 | 35 | 0.010 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2007 | 251 | 0.010 |
Why?
| | Cisterna Magna | 1 | 2002 | 7 | 0.010 |
Why?
| | Neuropsychological Tests | 1 | 2007 | 1306 | 0.010 |
Why?
|
|
Buvanendran's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|